Search clinical trials for: Almonertinib Pemetrexed/Cisplatin

Total 4025 results

Eli Lilly and Company

Completed

Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer

Gastric Cancer

Russian Federation
Shanghai Zhongshan Hospital

Not yet recruiting

Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Sensitivity
Eli Lilly and Company

Terminated

A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Small Cell Lung Cancer | SCLC | Carcinoma, Small Cell

Netherlands, Belgium
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
First People's Hospital of Hangzhou

Not yet recruiting

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Brain Metastases | EGFR Positive Non-small Cell Lung Cancer

China
University of Southern California
Sponsor Name Pending

Withdrawn

A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma

Mesothelioma

United States
Fudan University

Unknown

Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer

Local Advanced Non-Small Cell Lung Cancer

China
Shantou University Medical College

Unknown

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

Pleural Effusion, Malignant

China
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Anlotinib

China
Universität Duisburg-Essen
Eli Lilly and Company

Unknown

Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC (PemSplitCisp)

NSCLC

Germany
Li Zhang, MD

Recruiting

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
European Organisation for Research and Treatment...

Active, not recruiting

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Malignant Pleural Mesothelioma

Belgium, Netherlands
University of Arizona
National Cancer Institute (NCI)

Completed

Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
GlaxoSmithKline

Completed

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

Lung Cancer, Non-Small Cell

Denmark, United Kingdom
University Hospital, Brest

Completed

Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC) (GFPC 07-01)

Lung Cancer

France
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Mesothelioma, Malignant | Mesothelioma, Malignant Pleural | Mesothelioma Malignant Advanced

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Intergroupe Francophone de Cancerologie Thoracique
University Hospital, Caen; Groupe Français de Pneumo-Cancérologie

Completed

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS)

Mesothelioma

France
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Lung Cancer

China
Innate Pharma

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer

France, United States, Greece, Hungary, Poland
Memorial Sloan Kettering Cancer Center

Withdrawn

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
European Organisation for Research and Treatment...

Terminated

Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery

Lung Cancer

Belgium
University Hospital, Antwerp
Eli Lilly and Company; Universiteit Antwerpen

Completed

Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (PACCORA)

Non-Small Cell Lung Cancer

Belgium
UNICANCER

Completed

Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors (PACIFIK)

Metastatic Cancer | Solid Tumors

France
Spanish Lung Cancer Group

Terminated

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC (Phalcis)

Carcinoma, Non Small Cell Lung

Spain
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
Shanghai Chest Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)

Lung Cancer | EGFR Gene Mutation
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
EQRx, Inc.

Completed

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

NSCLC | Healthy Volunteers | Pharmacokinetics

United States, New Zealand
Roswell Park Cancer Institute

Completed

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Lung Cancer Metastatic

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Duke University
Eli Lilly and Company

Terminated

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703)

Carcinoma, Non-Small-Cell Lung

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
European Organisation for Research and Treatment...

Completed

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

Belgium, Italy, Netherlands, United Kingdom
Guangzhou Medical University

Completed

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Lung Adenocarcinoma | Brain Metastases

China
Qianfoshan Hospital
Shandong Provincial Hospital

Not yet recruiting

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer (MWA)

Advanced Non Small Cell Lung Cancer

China
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Poland, India, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation
Samsung Medical Center

Unknown

Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression

Non-small Cell Lung Cancer

Korea, Republic of
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery

Malignant Mesothelioma

United States
Duke University
Eli Lilly and Company

Terminated

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer (TOP0602)

Non Small Cell Lung Cancer

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Fudan University

Recruiting

Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma (ECTOP-1004)

Lung Neoplasms

China
Trans Tasman Radiation Oncology Group
National Health and Medical Research Council, Australia

Completed

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

Transitional Cell Carcinoma of Urinary Bladder

Australia, New Zealand
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation

3

Subscribe